Agenus Triggers First $20 Million Contingent Payment Under Zydus Collaboration
Agenus, a leader in immuno-oncology innovation, announced that it has triggered the first $20 million contingent payment under its previously disclosed strategic collaboration with Zydus Lifesciences Ltd.. The payment milestone represents an important step in advancing manufacturing and regulatory preparation for the company’s lead immunotherapy programs while strengthening the operational partnership between the two organizations.
Manufacturing Work Orders Initiate Payment Milestone
The $20 million payment was activated through contracted work orders related to essential chemistry, manufacturing and controls (CMC) activities and production operations associated with botensilimab (BOT) and balstilimab (BAL). These manufacturing activities enable Zydus to begin preparations for commercial-scale supply of Agenus’ leading immunotherapy candidates. The work also includes additional manufacturing processes required to satisfy regulatory readiness for Biologics License Application (BLA) and Marketing Authorization Application (MAA) submissions, supporting the programs’ advancement toward potential approvals in multiple global markets.
Building Supply for Expanding Clinical and Commercial Demand
The production activities will also help expand inventory levels to meet increasing demand expected across several areas of development and access. These include ongoing clinical development programs, authorized early access frameworks, and compassionate access pathways in certain countries. In addition, the manufacturing expansion is designed to prepare for potential global commercialization of the BOT and BAL combination therapy, ensuring adequate product availability once regulatory approvals are achieved.
First Operational Step with Zylidac Bio
This milestone represents the first operational activities conducted between Agenus and Zylidac Bio LLC, the U.S.-based biologics manufacturing subsidiary of Zydus Life Sciences. The collaboration establishes a critical manufacturing foundation that will support the long-term development and potential commercialization of Agenus’ immuno-oncology therapies while leveraging Zydus’ expertise in large-scale biologics production.
Leadership Perspective on Manufacturing Alignment
Garo H. Armen, Ph.D., Chairman and Chief Executive Officer of Agenus, emphasized the importance of the milestone in aligning manufacturing capabilities with the company’s clinical and regulatory progress. He noted that the activation of the contingent payment reflects Agenus’ commitment to advancing BOT and BAL toward regulatory approval while supporting clinical development efforts and compassionate access programs already underway. Armen highlighted that as reimbursed access continues in France through the AAC framework and named patient programs expand in other permitted regions, it becomes increasingly important for the company to proactively align manufacturing capacity with anticipated global demand.
Supporting Ongoing Clinical Trials and Access Programs
Agenus currently maintains sufficient cGMP clinical-grade drug product inventory of BOT and BAL to support several ongoing initiatives. These include the global BATTMAN Phase 3 clinical trial, the French early access program authorized by the national regulator, paid named-patient programs in certain countries where permitted, and multiple investigator-sponsored trials. The new manufacturing activities will supplement existing inventory levels while ensuring the company is prepared to meet rising demand across development, compassionate access, and potential future commercial distribution channels.
Structured Payments Enable Capital-Efficient Manufacturing
Under the strategic collaboration agreement between Agenus and Zydus, up to $50 million in contingent payments may be triggered through production orders related to BOT and BAL manufacturing. The $20 million milestone announced represents the first portion of this total and is specifically allocated to production and CMC-related work. This financial structure allows Agenus to execute essential manufacturing operations while preserving its capital position, as the payments directly fund production activities without requiring additional expenditures from the company’s balance sheet.
Long-Term Biologics Manufacturing Partnership
The collaboration between Agenus and Zydus was originally announced in June 2025 and officially completed in January 2026. The agreement provides Agenus with long-term access to U.S.-based biologics manufacturing capacity through Zydus’ infrastructure. This partnership is intended to support the continued development of the BOT and BAL immunotherapy combination while ensuring the manufacturing scale required for potential global commercialization in the future.
About Agenus
Agenus is an immuno-oncology company dedicated to developing innovative therapies that harness the immune system to fight cancer. Founded in 1994, the company focuses on expanding the number of patients who can benefit from cancer immunotherapy through combination treatment strategies. Its research portfolio includes antibody therapeutics, adoptive cell therapies through MiNK Therapeutics, and immunological adjuvants designed to enhance immune responses against tumors. Agenus operates integrated capabilities spanning research and discovery, global clinical development, and commercial-scale cGMP manufacturing. The company is headquartered in Lexington, Massachusetts, and maintains a global clinical and operational footprint supporting ongoing oncology research and therapeutic innovation.
Global Access Pathways for BOT+BAL
Until full regulatory approval is granted, the BOT and BAL combination therapy is currently available only through controlled access mechanisms. These include participation in clinical trials such as the Phase 3 BATTMAN study and authorized early access programs where permitted by national regulatory frameworks. These pathways allow eligible patients to receive investigational therapies prior to formal marketing authorization while enabling continued clinical evaluation of treatment outcomes.
Early Access Program in France
In France, eligible patients receiving BOT and BAL in hospitals may access treatment through the national early access program authorized by the country’s health authorities. Under this system, therapy is reimbursed through the national health insurance system once patients meet defined eligibility criteria. The reimbursement model covers the full course of treatment per patient under the national protocol rather than charging on a per-dose basis. After treatment authorization and initiation, the entire therapy course and all subsequent administrations are provided without additional product charges. In accordance with regulatory requirements, the maximum indemnity for the therapy is declared to the relevant French authorities.
Named-Patient Access Programs in Other Regions
Outside France, access to BOT and BAL may be available in certain countries through paid named-patient programs depending on local regulations. These programs enable physicians to request investigational therapies for individual patients who may not have access through clinical trials. Treatment costs in these programs may involve direct patient payment or special insurance coverage arrangements depending on regional healthcare policies and reimbursement frameworks.
About Botensilimab (BOT)
Botensilimab is a human Fc-enhanced multifunctional anti-CTLA-4 antibody designed to stimulate both innate and adaptive immune responses against tumors. The therapy incorporates mechanisms that may extend immunotherapy benefits to tumors considered “cold,” meaning they typically respond poorly to conventional treatments or existing PD-1 and CTLA-4 inhibitors. Botensilimab is designed to activate T cells, reduce regulatory T cells within tumors, stimulate myeloid immune cells, and promote durable immune memory responses that may support long-term tumor control.
About Balstilimab (BAL)
Balstilimab is a fully human monoclonal immunoglobulin G4 antibody that blocks the PD-1 immune checkpoint receptor from interacting with its ligands PD-L1 and PD-L2. By interrupting this pathway, the therapy helps restore immune system activity against cancer cells. Balstilimab has been evaluated in more than 900 patients across clinical studies and has demonstrated clinical activity along with a favorable tolerability profile in multiple tumor types. When used in combination with botensilimab, the therapy is designed to provide a complementary immunotherapy approach aimed at improving treatment outcomes for patients with difficult-to-treat cancers.
Source link:https://www.businesswire.com/
